Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer

作者：Arlene A. Forastiere, Helmuth Goepfert, Moshe Maor, Thomas F. Pajak, Randal S. Weber, William H. Morrison, Bonnie S. Glisson, Andy Trotti, John A. Ridge, C. Chao, Glen Peters, Ding-Jen Lee, Andrea Leaf, John F. Ensley, Jay S. Cooper · 发表于：New England Journal of Medicine · 年份：2003 · DOI：10.1056/nejmoa031317 · 被引用次数：3189 · 研究领域：Head and Neck Cancer Studies、Voice and Speech Disorders、Esophageal Cancer Research and Treatment

BACKGROUND: Induction chemotherapy with cisplatin plus fluorouracil followed by radiotherapy is the standard alternative to total laryngectomy for patients with locally advanced laryngeal cancer. The value of adding chemotherapy to radiotherapy and the optimal timing of chemotherapy are unknown. METHODS: We randomly assigned patients with locally advanced cancer of the larynx to one of three treatments: induction cisplatin plus fluorouracil followed by radiotherapy, radiotherapy with concurrent administration of cisplatin, or radiotherapy alone. The primary end point was preservation of the larynx. RESULTS: A total of 547 patients were randomly assigned to one of the three study groups. The median follow-up period was 3.8 years. At two years, the proportion of patients who had an intact larynx after radiotherapy with concurrent cisplatin (88 percent) differed significantly from the proportions in the groups given induction chemotherapy followed by radiotherapy (75 percent, P=0.005) or radiotherapy alone (70 percent, P<0.001). The rate of locoregional control was also significantly better with radiotherapy and concurrent cisplatin (78 percent, vs. 61 percent with induction cisplatin plus fluorouracil followed by radiotherapy and 56 percent with radiotherapy alone). Both of the chemotherapy-based regimens suppressed distant metastases and resulted in better disease-free survival than radiotherapy alone. However, overall survival rates were similar in all three groups. The rate ...